Skip to main content
SpringerLink
Log in

Gene therapy for rheumatoid arthritis: clinical studies

  • Chapter
Gene Therapy in Inflammatory Diseases

Part of the book series: Progress in Inflammation Research ((PIR))

  • 81 Accesses

Abstract

Collectively, over 35 million Americans suffer from the various arthritidies with an annual cost estimated to be greater than 18 billion dollars annually [1]. Rheumatoid arthritis (RA) is a progressive, autoimmune disease that primarily affects diarthro-dial joints. It has a world-wide incidence of approximately four per 10000 in the population aged greater than 15 years, and causes significant increases in morbidity and even mortality in affected patients [2–4]. 150 000 patients are diagnosed with RA each year in the United States at a cost of approximately $ 30 000 per case [5]. Women are twice as likely to be affected as men, and the prevalence increases with age. Although the prevalence of RA varies across the globe, no etiologic agents have been unequivocally identified [6–9].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Smyth C, Clayton M (1992) Medical perspectives of surgery for rheumatoid arthritis. In: Surgery for rheumatoid arthritis. Churchill, Livingstone, New York, 3–8

    Google Scholar 

  2. Lindgren JU (1996) Arthritis review. In: Orthopaedic knowledge update 5. American Academy of Orthopaedic Surgeons, IL, 169–171

    Google Scholar 

  3. Kaipiainen S, Aho K, Isomaki H, Laakso M (1996) Incidence of rheumatoid arthritis in Finland during 1980-1990. Ann Rheum Dis 55: 608–611

    Article  Google Scholar 

  4. Series V (1987) Rheumatology epidemiology. National Center for Health Statistics 10: 164

    Google Scholar 

  5. Harris E (1997) Clinical features of rheumatoid arthritis. In: Textbook of rheumatology, 5th ed. WB Saunders, Philadelphia, 898–933

    Google Scholar 

  6. Beasley R, Wilkens R, Bennett P (1973) High prevalence of rheumatoid arthritis in Yakima Indians. Arthritis Rheum 16: 743–748

    Article  PubMed  CAS  Google Scholar 

  7. Harvey J, Lotze M, Stevens M (1983) Rheumatoid arthritis in a Chippewa band. Rheumatology 10(1): 28–32

    CAS  Google Scholar 

  8. Solomon L, Robin G, Valkenberg H (1975) Rheumatoid arthritis in an urban South African Negro population. Ann Rheum Dis 34(2): 128–135

    Article  PubMed  CAS  Google Scholar 

  9. Lawrence J (1970) Rheumatoid arthritis: Nature or nurture? Ann Rheum Dis 29(4): 235–241

    Article  Google Scholar 

  10. Myllykangas R, Aho K, Isomaki H (1995) Mortality in rheumatoid arthritis. Sem Arthritis Rheum 25: 193–202

    Article  Google Scholar 

  11. Pincus T, Callahan L (1992) Early mortality in rheumatoid arthritis predicted by poor clinical status. Bull Rheum Dis 41: 1–4

    PubMed  CAS  Google Scholar 

  12. Moreland LW, Heck LW, Koopman WJ (1997) Biologic agents for treating rheumatoid arthritis. Arthritis Rheum 40: 397–409

    Article  PubMed  CAS  Google Scholar 

  13. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widner KM, Blosch CM (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337: 141–

    Article  PubMed  CAS  Google Scholar 

  14. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Anoni C, Smoler JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN (1994) Randomised, double blind comparison of a chimaeric: monoclonal antibody to tumor-necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105–1110

    Article  PubMed  CAS  Google Scholar 

  15. Drevlow BE, Louis R, Haag MA, Sinacore JM, Jacobs C, Blusche C, Landay A, More-land LW, Pope RM (1996) Recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 39: 257–265

    Article  PubMed  CAS  Google Scholar 

  16. Campion G, Lebsack M, Lookabough J, Gordon G, Catalano M (1996) Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 39: 1092–1101

    Article  PubMed  CAS  Google Scholar 

  17. Evans CH, Ghivizzani SC, Kang R, Muzzonigro T, Wasko MC, Herndon JH, Robbins PD (1999) Gene therapy for rheumatic diseases. Arthritis Rheum 42: 1–16

    Article  PubMed  CAS  Google Scholar 

  18. Bandara G, Robbins PD, Georgescu HI, Mueller GM, Glorioso JC, Evans CH (1992) Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol 11: 227–231

    Article  PubMed  CAS  Google Scholar 

  19. Arend WP, Dayer JM (1995) Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 38: 151–160

    Article  PubMed  CAS  Google Scholar 

  20. Schwab JH, Anderle SK, Brown RR, Dalldorf FR, Thompson RC (1989) Pro-and antiinflammatory effects of interleukin-1 in recurrence of bacterial, cell wall-induced arthritis in rats. Infect Immunol 59: 4436–4442

    Google Scholar 

  21. Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND (1993) The effect of interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 36: 1305–1312

    Article  PubMed  CAS  Google Scholar 

  22. Hung GL, Galea-lauri J, Mueller GM, Georgescu HI, Larkin LA, Tindal M., Robbins PD, Evans CH (1993) Suppression of intraarticular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Ther 1: 64–69

    Google Scholar 

  23. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH (1996) Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 156: 3558–3562

    PubMed  CAS  Google Scholar 

  24. Makarov SS, Olsen JC, Johnston TO, Anderle SK, Brown RR, Baldwin AS, Haskill JS, Schwab JH (1996) Suppression of experimental arthritis by gene transfer of interleukin-1 receptor antagonist cDNA. Proc Natl Acad Sci USA 93: 402–406

    Article  PubMed  CAS  Google Scholar 

  25. Bakker AC, Joosten LAB, Arntz OJ, Helser MMA, Bendele AM, Van De Loo FAJ, Van den Berg WB (1997) Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 40: 893–900

    Article  PubMed  CAS  Google Scholar 

  26. Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, Barranger JA, Elders EM, Gay S, Tomaino MM et al (1996) Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially antiarthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 7: 1261–1280

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA

    Thomas S. Muzzonigro & Richard Kang

  2. Departments of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA

    Mary C. Wasko

  3. Orthogen Gmbh, Düsseldorf, Germany

    Julio Reinecke & Peter Wehling

  4. Partners Department of Orthopaedic Surgery, Massachusetts General Hospital, Gray 624-55 Fruit Street, Boston, MA, 02114-2617, USA

    James H. Herndon

Authors
  1. Thomas S. Muzzonigro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julio Reinecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Wehling
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mary C. Wasko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. James H. Herndon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Molecular Orthopaedics, Harvard Medical School, 221 Longwood Avenue, Room BL 152, Boston, MA, 02115, USA

    Christopher H. Evans

  2. University of Pittsburgh School of Medicine, W1246, Biological Sciences Tower, Pittsburgh, PA, 15261, USA

    Paul D. Robbins

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Basel AG

About this chapter

Cite this chapter

Muzzonigro, T.S., Kang, R., Reinecke, J., Wehling, P., Wasko, M.C., Herndon, J.H. (2000). Gene therapy for rheumatoid arthritis: clinical studies. In: Evans, C.H., Robbins, P.D. (eds) Gene Therapy in Inflammatory Diseases. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8478-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8478-5_4

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9584-2

  • Online ISBN: 978-3-0348-8478-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation